Anavex Life Sciences Reports Promising Results in Parkinson Disease Dementia Study
Anavex Life Sciences has announced promising results from a 48-week open-label extension study of its investigational agent, ANAVEX2-73, also known as blarcamesine. The study aimed at evaluating the efficacy and safety of blarcamesine in patients with Parkinson disease dementia (PDD). The extension phase, although delayed due to the COVID-19 pandemic, demonstrated significant improvements in the […]